Loading annual review details
Kimball Electronics, Inc. (KE)FY2026 investor yearly review
Across FY2026, management leaned into its Medical CMO platform as a diversification engine while Automotive and Industrial faced ongoing end-market pressure. The year ended with improved cash generation and strengthened liquidity, while guidance pointed to continued Medical outperformance and an added inorganic growth lever through Helvoet.
Overall investor read
Constructive but execution-sensitive
Medical’s consistent double-digit cadence drove the recovery narrative, while cash conversion and facility ramp remained key swing factors.
Primary financial signal
$72.27M Free cash flow
Despite softer revenue, management delivered a positive full-year cash result and maintained a manageable net debt position.
Primary call signal
Helvoet adds growth + synergies
In Q4, management highlighted Helvoet integration and expected FY2027 contribution, framing it as accretive to the Medical-led plan.
Headline financial outcomes and year-end balance sheet snapshot.
Revenue
Down -3.7% YoY as Medical strength offset Automotive/Industrial pressure.
Gross margin
Improved off restructuring benefits and favorable mix through the year.
Operating margin
Held in the mid-single digits despite ongoing investments in Medical capacity.
Net income
Up strongly YoY, with effective tax and operating discipline contributing.
Diluted EPS
YoY improvement was large as net income translated to earnings power.
Free cash flow
Positive, but down YoY; investors watched working capital and cycle days.
Operating cash flow
Operating cash declined YoY, but remained positive and supportive of deleveraging.
Net debt
Low balance sheet leverage helped management fund Medical growth and acquisition plans.
Medical CMO became the year’s throughline, with cash stabilization and acquisition-led optionality replacing a purely cyclical narrative.
CMO acceleration
Management repeatedly tied Medical outperformance to a broader funnel and multiple customer/program sources. They highlighted ongoing production ramp planning for Indianapolis and emphasized that new programs have a 18-to-36-month path, with growth arriving through cadence shifts.
Quarter-by-quarter materiality and tone for annual transcript themes.
Scroll horizontally to see more columns.
| Theme | Q1 | Q2 | Q3 | Q4 | Next monitor |
|---|---|---|---|---|---|
| Medical CMO momentum and multi-quarter ramp cadence | Positive Medical strength drove results as Indianapolis capacity expanded | Positive |
Management improved cash conversion and gross margin through restructuring benefits while keeping the Medical CMO build on track; challenges were revenue softness, Automotive variability, and potential FY27 working capital pressure.
Management pointed to Medical’s repeated year-over-year growth and a funnel that remained high, with Q4 describing >10% growth after normalizing the prior-year consigned inventory event.
Across Q1–Q4, management attributed higher gross margin to favorable mix, closures/global restructuring, and operating leverage as costs were aligned to demand and Tampa fixed costs were removed.
Revenue and margin narratives moved from Medical-led offsetting in Q1 to broader stabilization by Q4, while cash conversion and facility ramp shaped investor monitoring throughout.
Gross margin improved; working capital remained a swing factor
Q1 established Medical as the stabilizing growth vertical amid Automotive and Industrial declines. Q2 raised outlook as Medical momentum persisted, while Indy ramp costs became a stated margin drag. Q3 reinforced that normalized comparisons still showed Medical strength and that gross margin pressure would likely extend into FY27. Q4 ended with improved cash generation, deleveraging, and a broadened growth plan through Helvoet and Medical-led guidance for FY2027.
Management opened the year with Medical sales strength and acknowledged Automotive/Industrial declines, while highlighting gross margin improvement from restructuring actions and a positive cash-flow run.
Read earnings transcriptAs Medical delivered another quarter of double-digit growth, management raised FY2026 net sales guidance and described Indy facility opening as a near-term drag, balancing investments with cost alignment work.
Guidance was provided directionally and then raised; reported year-end results broadly aligned with the renewed outlook as management described a Medical-led finish.
$1.35B to $1.45B; adjusted operating income 4% to 4.25%
Revenue $1.43B; Other 4.6%
Q1 guidance ranges were hit on revenue, and adjusted operating performance ultimately came in higher than the mid-4% target range management reiterated.
$1.4B to $1.46B; adjusted operating income 4.2% to 4.5%
Revenue $1.43B; Other 4.6%
Management’s raised outlook in Q2 stayed credible into the year, with actual revenue in-range and operating income ending slightly above the upper band.
Key items to monitor center on the Medical ramp and facility cost absorption, plus how working capital reacts as supply-chain conditions normalize or disrupt.
Medical-led growth is the year’s core stabilization lever for the portfolio and margin profile.
Medical share of sales, new facility production timing, and comments on ramp of new programs.
Facility ramp costs can compress margins before revenue catches up, influencing earnings quality expectations.
Facility execution
Throughout the year, management described the Indianapolis facility as necessary for higher-value Medical manufacturing, but acknowledged near-term margin drag from depreciation and operating costs. By Q4, management quantified FY2027 gross-margin pressure expectations and framed Helvoet as offsetting elements.
Automotive variability
Automotive performance oscillated quarter to quarter as management pointed to tariff pressure, program anniversary effects, and underperformance versus initial EV demand assumptions. In Q4, management characterized declines as driven by EV program volume shortfalls rather than program losses, guiding toward eventual stabilization.
Cash discipline
Management emphasized improved cash conversion days early and highlighted operational initiatives that supported consecutive quarters of positive cash flow. In Q4, they also warned that inventory disruption and “golden screw” type events could pressure working capital in FY2027, implying cash metrics would remain watched.
Medical delivered fourth straight YoY growth and outpaced
Positive Adjusted Medical growth persisted; funnel remained high |
Positive Medical led fiscal year growth across all quarters |
| Track Medical share of sales and Indianapolis ramp commentary across Q1–Q2. |
| Indianapolis facility ramp cost drag versus margin recovery path | Neutral Tariff and North America pressure dominated margin talk | Mixed Facility opening drag acknowledged during grand opening ramp | Mixed Gross margin expected under pressure in FY27 | Mixed Management quantified ongoing drag timing and offset framing | Watch gross margin guidance, S&A level, and statements on transfer vs incremental growth. |
| Automotive stabilization tied to program volumes and EV demand | Negative Automotive declined as braking program moved out | Negative Tariff and China softness hit North America automotive | Mixed Poland and Romania ramps offset EV-linked pressure | Mixed Stabilizing trend framed as EV volume underperformance | Monitor Automotive commentary on EV incentives/regulations and new program ramp rates. |
| Working capital improvement initiatives and potential FY27 pressure | Positive Cash conversion improved; seventh consecutive positive cash flow | Mixed Cash conversion days ticked up as inventory rose | Positive CCD improved again; inventory continued working down | Mixed Management warned of inventory disruption pressure in FY27 | Track CCD and inventory commentary, especially mention of “golden screw” events and DSO. |
| Helvoet acquisition integration added inorganic growth option | Positive Helvoet included in FY27 outlook with synergy focus | Watch FY2027 Helvoet revenue contribution and integration milestones referenced for synergies. |
| Strategic M&A discipline focused on Medical CMO fit and pricing rationality | Positive Management reiterated disciplined tuck-in approach for Medical CMO | Positive Acquisitions described as discipline in customer and capability adds | Positive M&A criteria centered on tuck-ins and capacity utilization | Positive Helvoet integration described as on track and synergistic | Monitor Medical adjacency targets and management language on tuck-in size and integration progress. |
Management described consecutive quarters of positive cash flow and in Q4 stated cash from operations was used to pay down debt to its lowest level in over four years, reinforcing dry powder.
In Q2, management linked momentum to rebranding as Kimball Solutions and grand opening of Indianapolis, positioning the expanded portfolio to attract Medical CMO opportunities.
Management repeatedly described declines in Automotive and Industrial from tariff impacts, HVAC softness, and EV program demand challenges, resulting in a full-year top-line contraction.
Management acknowledged that Indianapolis ramp costs would drag margins in the near term and later guided FY27 gross margin pressure that would require revenue to cover fixed costs, creating execution sensitivity.
Management said the biggest pressure was demand for already-awarded programs versus expectations, with EV demand fluctuations and China competition shaping the quarter-by-quarter narrative.
In Q4, management flagged inventory disruption in the supply chain and “golden screw” type events, expecting working capital to rise a few days in FY27.
Scroll horizontally to see more columns.
| Quarter | Revenue | YoY revenue growth | Diluted EPS | Gross margin | Investor read |
|---|---|---|---|---|---|
| Q1Sep-25 | $365.6M | -3.9% | $0.4 | 7.9% | Medical was the offsetting engine early in the year, with margins up and cash generation staying positive. |
| Q2Dec-25 | $341.28M | -6.7% | $0.15 | 8.2% | Raised guidance was tied to Medical and Automotive ramps, but investors were told the Indy ramp would weigh on margins temporarily. |
| Q3Mar-26 | $352.92M | 3.4% | $0.23 | 7.4% | Investors saw a cleaner normalized Medical story after the prior-year consigned inventory sale and an explicit FY27 margin caution. |
| Q4Jun-26 | $371.57M | 5.3% | $0.35 | 8.9% | Medical led FY2026 growth across quarters, and FY2027 was framed as return-to-growth with acquisition synergies and facility timing caveats. |
Management noted that comparisons were distorted by a prior-year consigned inventory sale and that normalized Medical still grew, while explicitly guiding gross margin pressure in FY27 from Indy ramp costs.
Read earnings transcriptManagement characterized the year as a strong finish with debt reduction and best-in-recent-period cash conversion, then connected FY2027 return-to-growth guidance to Medical outperformance and Helvoet integration, alongside working capital cautions.
Read earnings transcript$1.4B to $1.46B; adjusted operating income margin high end of 4.2% to 4.5%
Revenue $1.43B; Other 4.6%
Q3 affirmed revenue guidance and indicated a high-end operating margin outcome; FY2026 ended just above the stated margin band.
FY2026 revenue range $1.4B to $1.46B (affirmed through Q4 commentary); adjusted operating income 4.4% to 4.7%
Revenue $1.43B; Other 4.6%
At year-end, management’s setup implied performance within a targeted operating margin band, which the reported full-year operating margin roughly matched.
Gross margin guidance and management language about drag timing, transfer vs incremental growth impacts.
Working capital volatility can shift the cash-to-earnings bridge even when operating income looks stable.
Cash conversion days (CCD) and DSO/DPO discussion, including “golden screw” and inventory disruption references.
Automotive stabilization depends on program volume recovery versus original expectations and macro/regulatory conditions.
Management’s updates on EV demand, incentive/regulatory changes, and whether steering/braking programs meet volume assumptions.
Inorganic growth and cross-selling may change FY2027 expectations and how the Medical-led plan is funded.
Helvoet revenue contribution, integration milestones, and management notes on top-line synergy realization timeline.
Dafinchi